NCT01252732View on ClinicalTrials.gov

Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection

PHASE3CompletedINTERVENTIONAL
Enrollment

1,019

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Wound InfectionAbscessSystemic InflammationCellulitis
Interventions
DRUG

Single-Dose IV Oritavancin Diphosphate

Intravenous oritavancin and IV placebo or IV vancomycin will be administered for a minimum of 7 days up to a maximum of 10 days.

DRUG

IV Vancomycin

Intravenous oritavancin and IV placebo or IV vancomycin will be administered for a minimum of 7 days up to a maximum of 10 days.

Trial Locations (1)

91942

Sharp Grossmont Hospital, La Mesa

Sponsors
All Listed Sponsors
lead

Melinta Therapeutics, Inc.

INDUSTRY